近日，全球领先的乳清原料供应商阿拉食品原料（Arla Foods Ingredients）推出一款即溶冲调型乳清蛋白原料——Lacprodan®BLG-100 Acidic。 这款原料专为特医食品定制，直面当前临床营养品普遍存在的"口感差、难坚持"等痛点，旨在为患者打造更可口、便捷的高蛋白饮品，帮助患 者轻松补充营养，提升日常饮用体验与依从性。 临床营养现状：营养不良常见，产品依从性不佳 世界卫生组织的研究表明，高达 50% 的住院患者存在营养不良问题，而营养不良往往会导致住院时间延长、生活质量下降、死亡率增加以及 医疗成本升高[1]。然而，对于食欲减退的患者而言，通过口服营养补充剂摄入足量蛋白质本身就是一项不小的挑战。多项全球性调研显示， 约半数患者未能遵循其临床营养方案，其中产品口味和质地被反复提及，是影响依从性的关键因素之一[2]。 长期以来，临床营养市场主要由单一的乳基即饮型饮料和冲调粉剂所主导，这类产品因其配方设计通常局限于中性 pH 值范围，往往口感偏黏 稠，清爽度不足；而相对清爽的果汁类产品则基本局限于即饮形式，缺乏灵活应用的选择。多项专业调研均指出，无论是患者还是医护专业人 员，都在寻求更灵活 ...

Core Viewpoint - Zhejiang Zuoli Pharmaceutical Co., Ltd. announced the acquisition of core assets related to multi-trace element injection solutions from Tibet Future Biopharmaceutical Co., Ltd. for 356 million yuan (including tax) [1] Group 1: Acquisition Details - The asset group includes already marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)", along with relevant R&D and production technical data, marketing licenses, trademarks, patents, contractual rights and obligations, and employee labor relations [2] - The "Multi-trace Element Injection (I)" is the first exclusive pediatric-specific parenteral nutrition preparation in China, with very few companies holding the relevant approvals for such products, creating a natural high market barrier [2] Group 2: Company Performance - Zuoli Pharmaceutical has shown a strong growth trend, achieving a revenue of 2.28 billion yuan in the first three quarters of 2025, a year-on-year increase of 11.48%, and a net profit attributable to shareholders of 510 million yuan, up 21.00% year-on-year [3] - The company has developed a product matrix centered around Wuling Capsules, with a focus on expanding into lower-tier markets and enhancing clinical value recognition through targeted marketing strategies [3] Group 3: Strategic Advantages - The company can leverage its market advantages in centralized procurement and essential drug products to synergize with the multi-trace element injection product group, meeting the growing diversified clinical needs [4] - This acquisition is expected to enhance the company's marketing capabilities and team potential, facilitating rapid market entry and deep penetration of the new products [4]